Announces Collaboration and Secures Exclusive
License with KR8.ai to Power New Epigenetic Wellness Solutions
FOXO Technologies Inc. (NYSE American: FOXO)
(“FOXO” or the “Company”), a leader in the field of commercializing
epigenetic biomarker technology, today announced plans for a new
subscription-based, direct-to-consumer product offering that will
provide personalized health and wellness recommendations, by
combining: (i) FOXO’s machine learning models to analyze epigenetic
biomarkers; (ii) the Company’s expertise and algorithms correlating
epigenetic analysis with health outcomes; and (iii) published,
peer-reviewed, clinical data and other verified, third-party health
resources. In connection with the new offering, the Company also
announced it has formed a collaboration with KR8.ai Inc. (“KR8”)
and secured an exclusive license to KR8’s AI-based software to
support the development and commercial launch of the new health and
wellness offering.
Mark White, Interim CEO of FOXO Technologies, stated, “We are
excited to formally unveil plans for our new direct-to-consumer
offering. This strategy is designed to leverage our epigenetic data
and analytics, which we believe reflects our core strength and
includes some of the most advanced capabilities in the industry.
Epigenetics is central to understanding how genes are regulated and
how lifestyle and environmental influences interact with our
biological systems. Fully unlocking the value of epigenetic data
has been a challenge due to complexities in data processing and
interpretation. By integrating KR8’s advanced AI software, we
intend to launch a best-in-class health and wellness offering,
including a new consumer app, which will provide individuals with
personalized insights to understand their biological age and
optimize health. Getting started would simply require users to send
a saliva or blood sample and the technology will then combine this
information with user health stats, from readily available sources
and third-party apps. Moreover, we intend to combine these inputs,
through the power of AI, with massive health data sets, such as
peer-reviewed clinical studies and other verified health resources,
to provide a comprehensive risk analysis and actionable health
insights. By leveraging the KR8 software with FOXO’s epigenetic
expertise and growing patent estate, we look forward to empowering
consumers to better manage their own health.”
“To enhance our commercial launch, we look forward to
integrating KR8’s AI-driven analytic software and proprietary
algorithms to cost-effectively drive social media campaigns, as
well as leverage their broad network of social media influencers
with a goal of rapidly scaling FOXO’s new direct-to-consumer
offering. They have a proven track record working with leading
brands, and I truly believe they are the ideal partner for this new
endeavor. According to Verified Market Research, the Health and
Fitness App Market size was valued at $8.2 billion in 2022 and is
projected to reach $35.7 billion by 2030. We believe we are well
positioned to capture a meaningful share of this market through an
unparalleled offering that goes way beyond traditional health apps,
coupled with a cost-effective go-to-market strategy. We look
forward to providing regular updates on our progress in the weeks
and months ahead, including the product branding, integration with
other health apps, launch dates and much more,” concluded Mr.
White.
Spencer Cliff Christopher, Founder and Chief Technology Officer
of KR8, stated, “We are thrilled to announce our strategic
partnership with FOXO, an exemplary leader within the epigenetic
domain. The integration of KR8’s robust artificial intelligence
capabilities with FOXO’s unparalleled expertise in genetics is
poised to redefine the standards of wellness coaching. This
collaboration underscores our unwavering dedication to innovation
and our commitment to empowering individuals with personalized,
data-driven insights for their health and well-being. As we embark
on this exciting venture, we are confident that this synergy of
genetic insight and precision AI will establish a new standard in
personalized wellness, offering users an unmatched level of
guidance and support. We look forward to not just using AI as a
tool, but as a companion in people's health journey.”
About KR8.ai
KR8.ai harnesses the power of AI-driven analytics to optimize
social media accounts’ current performance against their full
potential.. Their premier mobile application, aptly named 'the KR8
Coach', provides a comprehensive evaluation of an account’s current
performance against their full potential. Based on this analysis,
it then offers intelligent, AI-derived suggestions to amplify the
reach and effectiveness of their posts. Beyond this, KR8 AI's
innovative solutions are adaptable and can seamlessly be integrated
into third-party, direct-to-consumer applications. This
adaptability not only streamlines processes but also results in
more economically efficient technology implementations.
About FOXO Technologies Inc. (“FOXO”)
FOXO, a technology platform company, is a leader in epigenetic
biomarker discovery and commercialization focused on
commercializing longevity science through products and services
that serve multiple industries. FOXO's epigenetic technology
applies AI to DNA methylation to identify molecular biomarkers of
human health and aging. For more information about FOXO, visit
www.foxotechnologies.com. For investor information and updates,
visit https://foxotechnologies.com/investors/.
Forward-Looking Statements
This press release contains certain forward-looking statements
for purposes of the “safe harbor” provisions under the United
States Private Securities Litigation Reform Act of 1995. Any
statements other than statements of historical fact contained
herein, including statements as to future results of operations and
financial position, planned products and services, business
strategy and plans, objectives of management for future operations
of FOXO, market size and growth opportunities, competitive
position, and technological and market trends, are forward-looking
statements. Such forward-looking statements include, but not
limited to, expectations, hopes, beliefs, intentions, plans,
prospects, financial results or strategies regarding FOXO; the
future financial condition and performance of FOXO and the products
and markets and expected future performance and market
opportunities of FOXO. These forward-looking statements generally
are identified by the words “anticipate,” “believe,” “could,”
“expect,” “estimate,” “future,” “intend,” “strategy,” “may,”
“might,” “strategy,” “opportunity,” “plan,” project,” “possible,”
“potential,” “project,” “predict,” “scales,” “representative of,”
“valuation,” “should,” “will,” “would,” “will be,” “will continue,”
“will likely result,” and similar expressions, but the absence of
these words does not mean that a statement is not forward-looking.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to: (i) the risk of changes in
the competitive and highly regulated industries in which FOXO
operates, variations in operating performance across competitors or
changes in laws and regulations affecting FOXO’s business; (ii) the
ability to implement FOXO’s business plans, forecasts, and other
expectations; (iii) the ability to obtain financing if needed; (iv)
the ability to maintain its NYSE American listing; (v) the risk
that FOXO has a history of losses and may not achieve or maintain
profitability in the future; (vi) potential inability of FOXO to
establish or maintain relationships required to advance its goals
or to achieve its commercialization and development plans; (vii)
the enforceability of FOXO’s intellectual property, including its
patents and the potential infringement on the intellectual property
rights of others; and (viii) the risk of downturns and a changing
regulatory landscape in the highly competitive biotechnology
industry or in the markets or industries in which FOXO’s
prospective customers operate. The foregoing list of factors is not
exhaustive. Readers should carefully consider the foregoing factors
and the other risks and uncertainties discussed in FOXO’s most
recent reports on Forms 10-K and 10-Q, particularly the “Risk
Factors” sections of those reports, and in other documents FOXO has
filed, or will file, with the SEC. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and FOXO assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231030522965/en/
Crescendo Communications, LLC (212) 671-1020
foxo@crescendo-ir.com
FOXO Technologies (AMEX:FOXO)
Historical Stock Chart
From Jul 2024 to Aug 2024
FOXO Technologies (AMEX:FOXO)
Historical Stock Chart
From Aug 2023 to Aug 2024